Glass Lewis Backs Aptose-Hanmi Deal as Shareholder Vote Nears
Event summary
- Glass Lewis recommends Aptose shareholders vote 'FOR' the Hanmi Pharmaceutical acquisition deal
- Special shareholder meeting reconvened for March 31, 2026 after SEC comments delayed initial vote
- Transaction requires court and TSX approval to complete
- Aptose board unanimously supports both the arrangement and corporate continuance to Alberta jurisdiction
The big picture
The Glass Lewis endorsement strengthens the likelihood of shareholder approval for Aptose's acquisition by Hanmi Pharmaceutical, a deal that would represent a significant shift in ownership for the clinical-stage biotech company. This transaction comes amid increased consolidation activity in the oncology-focused biopharmaceutical sector as larger players seek to expand their pipelines with promising cancer therapeutics.
What we're watching
- Regulatory Compliance
- Whether SEC concerns will impact the timing or terms of the transaction completion
- Shareholder Approval
- The level of shareholder turnout and support for the deal given Glass Lewis' endorsement
- Operational Continuity
- How the transition to Alberta jurisdiction may affect Aptose's corporate operations
Related topics